Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon
Managing Director, Fleta Solomon
Source: Little Green Pharma
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Little Green Pharma (LGP) has exported over 1000 units of medicinal cannabis oil to the U.K. as part of consignment sales agreement with LYPHE Group
  • LYPHE has a significant presence in the United Kingdom and writes over half of all new medicinal cannabis prescriptions
  • As part of the agreement, LYPHE will prescribe and dispense the company’s medicinal cannabis products to patients while reporting the efficacy, safety and patient outcomes
  • This deal is significant as it further cements Little Green Pharma’s presence in the U.K. and European markets
  • Furthermore, it expects to ship its first export order to Germany by the December quarter
  • Company shares are up a slight 2.82 per cent and are trading for 36.5 cents each

Little Green Pharma (LGP) has exported over 1000 units of medicinal cannabis oil to the U.K. as part of consignment sales agreement with LYPHE Group.

LYPHE is the parent company of Astral Health, to whom the company delivered a pathfinder shipment in mid-April.

Importantly, LYPHE has a significant presence in the United Kingdom and writes over half of all new medicinal cannabis prescriptions in the nation.

Under the sales agreement, LYPHE will prescribe and dispense Little Green Pharma’s medicinal cannabis products to patients at its clinics. Simultaneously, LYPHE will be responsible for reporting data investigating efficacy, safety, quality of life, and patient-reported outcomes to Little Green Pharma.

Despite sales and revenue having a small chance of being financially material, this shipment represents a key step towards the company’s goal of meeting the growing demand by patients wanting access to medicinal cannabis in the U.K. and across Europe.

Little Green Pharma expects it will receive its expanded Cultivation and Production Permit shortly. This permit will provide further cultivation capacity to help it meet the demand in the U.K. and Europe.

Furthermore, LGP anticipates making its first export of medicinal cannabis products to Germany by the December quarter.

Company shares are up a slight 2.82 per cent and are trading for 36.5 cents each at market close.

LGP by the numbers
More From The Market Online
Disability NDIS concept

Freedom Care Group reveals NDIS wants to ban it providing program services

Shares in Freedom Care Group (ASX:FCG) were down more than -3% on Wednesday after revealing the…
Image representing bacterial infections in the immune system

Recce reaches key dosing milestone in testing of skin infection gel

Recce Pharmaceuticals Ltd has successfully dosed 20 out of 30 participants in its Phase II trial…
Bank of England London town

Wellnex bumps first $3M payment for Pain Away into 1Q25 – when it lists in London

Wellnex Life Ltd (ASX:WNX) has unveiled its plans to defer a $2.95M payment to 360 Health…
DNA RNA therapy concept

PYC Therapeutics moves into final stage of child blindness study

PYC has been approved to escalate doses of its drug candidate VP-001, treating Retinitis Pigmentosa 11,…